Edward C. Saltzman
Ed is Head, Biotech Strategy for Lumanity. He is the founder of Defined Health one of the premier strategy advisories in biopharma and one of the earliest to focus their efforts on the emerging biotech sector. After having led the sale of Defined Health to Cello Health in 2017, Ed took on the role of Executive Chairman of Cello’s biotech business unit. Ed possesses a vast knowledge of the pharmaceutical and biotechnology industry accumulated over Defined Health’s 25+ years of consultancy to pharma, biotech, specialty pharma and investors.
Ed is also a well-regarded and in demand speaker on industry issues and has been recognized widely as an early “spotter” of key trends that go on to have significant impact within the life sciences industry, especially as these pertain to the licensing and business development field. In addition to industry conference and other public events, Ed has presented targeted strategy briefings and held discussions privately with scores of boards of directors, executive management committees and licensing and business development teams at large pharma, specialty pharma and biotech companies as well with the leading life sciences venture capital firms. He notably coined the term “Proof of Relevance,” to describe indisputable demonstration of clinical and economic value in drug development. He is a recent recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector.
Ed held prior positions at the Ayerst Laboratories unit of American Home Products, where he had responsibility for evaluation and forecasting of compounds being considered for licensing, and at FIND/SVP, where he managed the Healthcare Information Center.
Ed serves on the Board at Nurix Therapeutics and as a Venture Advisor to the Israel Biotech Fund and Hibiscus Capital Management. Prior Board roles include Vidac Pharmaceuticals, Saniona AB as well as numerous strategic advisory boards. He is a graduate of New York University.